A citation-based method for searching scientific literature

Justus M Huelse, Diana M Fridlyand, Shelton Earp, Deborah DeRyckere, Douglas K Graham. Pharmacol Ther 2020
Times Cited: 20







List of co-cited articles
197 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Yi Zhou, Mingjian Fei, Gu Zhang, Wei-Ching Liang, WeiYu Lin, Yan Wu, Robert Piskol, John Ridgway, Erin McNamara, Haochu Huang,[...]. Immunity 2020
118
50

The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.
Douglas K Graham, Deborah DeRyckere, Kurtis D Davies, H Shelton Earp. Nat Rev Cancer 2014
405
45


MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Alisa B Lee-Sherick, Kristen M Jacobsen, Curtis J Henry, Madeline G Huey, Rebecca E Parker, Lauren S Page, Amanda A Hill, Xiaodong Wang, Stephen V Frye, H Shelton Earp,[...]. JCI Insight 2018
38
40

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Rebecca S Cook, Kristen M Jacobsen, Anne M Wofford, Deborah DeRyckere, Jamie Stanford, Anne L Prieto, Elizabeth Redente, Melissa Sandahl, Debra M Hunter, Karen E Strunk,[...]. J Clin Invest 2013
111
40

Phagocytosis and clearance of apoptotic cells is mediated by MER.
R S Scott, E J McMahon, S M Pop, E A Reap, R Caricchio, P L Cohen, H S Earp, G K Matsushima. Nature 2001
862
35

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Weihe Zhang, Deborah DeRyckere, Debra Hunter, Jing Liu, Michael A Stashko, Katherine A Minson, Christopher T Cummings, Minjung Lee, Trevor G Glaros, Dianne L Newton,[...]. J Med Chem 2014
91
30

MerTK as a therapeutic target in glioblastoma.
Jing Wu, Lauren N Frady, Ryan E Bash, Stephanie M Cohen, Allison N Schorzman, Yu-Ting Su, David M Irvin, William C Zamboni, Xiaodong Wang, Stephen V Frye,[...]. Neuro Oncol 2018
42
30

Immunobiology of the TAM receptors.
Greg Lemke, Carla V Rothlin. Nat Rev Immunol 2008
563
25

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
Deborah DeRyckere, Alisa B Lee-Sherick, Madeline G Huey, Amanda A Hill, Jeffrey W Tyner, Kristen M Jacobsen, Lauren S Page, Gregory G Kirkpatrick, Fatma Eryildiz, Stephanie A Montgomery,[...]. Clin Cancer Res 2017
38
25

TAM receptor signaling in immune homeostasis.
Carla V Rothlin, Eugenio A Carrera-Silva, Lidia Bosurgi, Sourav Ghosh. Annu Rev Immunol 2015
254
25

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.
Marka R Crittenden, Jason Baird, David Friedman, Talicia Savage, Lauren Uhde, Alejandro Alice, Benjamin Cottam, Kristina Young, Pippa Newell, Cynthia Nguyen,[...]. Oncotarget 2016
61
25

T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response.
Eugenio A Carrera Silva, Pamela Y Chan, Leonel Joannas, Andrea E Errasti, Nicola Gagliani, Lidia Bosurgi, Maurice Jabbour, Anthony Perry, Faye Smith-Chakmakova, Daniel Mucida,[...]. Immunity 2013
117
20


Cloning and mRNA expression analysis of a novel human protooncogene, c-mer.
D K Graham, T L Dawson, D L Mullaney, H R Snodgrass, H S Earp. Cell Growth Differ 1994
259
20

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
R M A Linger, R A Cohen, C T Cummings, S Sather, J Migdall-Wilson, D H G Middleton, X Lu, A E Barón, W A Franklin, D T Merrick,[...]. Oncogene 2013
140
20

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Amira A Barkal, Rachel E Brewer, Maxim Markovic, Mark Kowarsky, Sammy A Barkal, Balyn W Zaro, Venkatesh Krishnan, Jason Hatakeyama, Oliver Dorigo, Layla J Barkal,[...]. Nature 2019
417
20

Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Canan Kasikara, Viralkumar Davra, David Calianese, Ke Geng, Thomas E Spires, Michael Quigley, Michael Wichroski, Ganapathy Sriram, Lucia Suarez-Lopez, Michael B Yaffe,[...]. Cancer Res 2019
50
20

Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Erin D Lew, Jennifer Oh, Patrick G Burrola, Irit Lax, Anna Zagórska, Paqui G Través, Joseph Schlessinger, Greg Lemke. Elife 2014
162
20

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Alisha Holtzhausen, William Harris, Eric Ubil, Debra M Hunter, Jichen Zhao, Yuewei Zhang, Dehui Zhang, Qingyang Liu, Xiaodong Wang, Douglas K Graham,[...]. Cancer Immunol Res 2019
52
20

TAM receptors are pleiotropic inhibitors of the innate immune response.
Carla V Rothlin, Sourav Ghosh, Elina I Zuniga, Michael B A Oldstone, Greg Lemke. Cell 2007
702
20

Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.
Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, Glenn K Matsushima. J Immunol 2007
271
20

Molecular pathways: MERTK signaling in cancer.
Christopher T Cummings, Deborah Deryckere, H Shelton Earp, Douglas K Graham. Clin Cancer Res 2013
73
20

Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Wen-I Tsou, Khanh-Quynh N Nguyen, Daniel A Calarese, Scott J Garforth, Anita L Antes, Sergey V Smirnov, Steve C Almo, Raymond B Birge, Sergei V Kotenko. J Biol Chem 2014
140
20

Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
Junsong Zhou, Aizhen Yang, Yucan Wang, Fengwu Chen, Zhenzhen Zhao, Viralkumar Davra, Katsue Suzuki-Inoue, Yukio Ozaki, Raymond B Birge, Qingxian Lu,[...]. Cell Commun Signal 2018
12
25


Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Alisa B Lee-Sherick, Weihe Zhang, Kelly K Menachof, Amanda A Hill, Sean Rinella, Gregory Kirkpatrick, Lauren S Page, Michael A Stashko, Craig T Jordan, Qi Wei,[...]. Oncotarget 2015
33
15

Structural insights into the inhibited states of the Mer receptor tyrosine kinase.
Xudong Huang, Patrick Finerty, John R Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A Parker, Benjamin E Turk, Debra A Thompson, Sirano Dhe-Paganon. J Struct Biol 2009
41
15


Galectin-3 is a new MerTK-specific eat-me signal.
Nora B Caberoy, Gabriela Alvarado, Jo-Lawrence Bigcas, Wei Li. J Cell Physiol 2012
118
15


Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.
Weihe Zhang, Dehui Zhang, Michael A Stashko, Deborah DeRyckere, Debra Hunter, Dmitri Kireev, Michael J Miley, Christopher Cummings, Minjung Lee, Jacqueline Norris-Drouin,[...]. J Med Chem 2013
45
15

Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase.
Philip L Cohen, Roberto Caricchio, Valsamma Abraham, Todd D Camenisch, J Charles Jennette, Robert A S Roubey, H Shelton Earp, Glenn Matsushima, Elizabeth A Reap. J Exp Med 2002
481
15


A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.
Susan Sather, Karla D Kenyon, Jerry B Lefkowitz, Xiayuan Liang, Brian C Varnum, Peter M Henson, Douglas K Graham. Blood 2007
220
15

Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Christopher T Cummings, Weihe Zhang, Kurtis D Davies, Gregory D Kirkpatrick, Dehui Zhang, Deborah DeRyckere, Xiaodong Wang, Stephen V Frye, H Shelton Earp, Douglas K Graham. Mol Cancer Ther 2015
38
15

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Magdalena Paolino, Axel Choidas, Stephanie Wallner, Blanka Pranjic, Iris Uribesalgo, Stefanie Loeser, Amanda M Jamieson, Wallace Y Langdon, Fumiyo Ikeda, Juan Pablo Fededa,[...]. Nature 2014
287
15

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Amira A Barkal, Kipp Weiskopf, Kevin S Kao, Sydney R Gordon, Benyamin Rosental, Ying Y Yiu, Benson M George, Maxim Markovic, Nan G Ring, Jonathan M Tsai,[...]. Nat Immunol 2018
223
15

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Branimir I Sikic, Nehal Lakhani, Amita Patnaik, Sumit A Shah, Sreenivasa R Chandana, Drew Rasco, A Dimitrios Colevas, Timothy O'Rourke, Sujata Narayanan, Kyriakos Papadopoulos,[...]. J Clin Oncol 2019
226
15

Macrophages as regulators of tumour immunity and immunotherapy.
David G DeNardo, Brian Ruffell. Nat Rev Immunol 2019
704
15

Phagocytosis checkpoints as new targets for cancer immunotherapy.
Mingye Feng, Wen Jiang, Betty Y S Kim, Cheng Cheng Zhang, Yang-Xin Fu, Irving L Weissman. Nat Rev Cancer 2019
286
15

Targeting macrophages: therapeutic approaches in cancer.
Luca Cassetta, Jeffrey W Pollard. Nat Rev Drug Discov 2018
714
15

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Amy K Keating, Grace K Kim, Ashley E Jones, Andrew M Donson, Kathryn Ware, Jean M Mulcahy, Dana B Salzberg, Nicholas K Foreman, Xiayuan Liang, Andrew Thorburn,[...]. Mol Cancer Ther 2010
114
15

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
Katherine A Minson, Catherine C Smith, Deborah DeRyckere, Clara Libbrecht, Alisa B Lee-Sherick, Madeline G Huey, Elisabeth A Lasater, Gregory D Kirkpatrick, Michael A Stashko, Weihe Zhang,[...]. JCI Insight 2016
36
15

Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme.
Y Wang, G Moncayo, P Morin, G Xue, M Grzmil, M M Lino, V Clément-Schatlo, S Frank, A Merlo, B A Hemmings. Oncogene 2013
54
15

MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.
Yu-Ting Su, Madison Butler, Meili Zhang, Wei Zhang, Hua Song, Lee Hwang, Andy D Tran, Ryan E Bash, Allison N Schorzman, Ying Pang,[...]. Neurooncol Adv 2020
9
33

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Sacha J Holland, Alison Pan, Christian Franci, Yuanming Hu, Betty Chang, Weiqun Li, Matt Duan, Allan Torneros, Jiaxin Yu, Thilo J Heckrodt,[...]. Cancer Res 2010
353
15

BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module.
Daeho Park, Annie-Carole Tosello-Trampont, Michael R Elliott, Mingjian Lu, Lisa B Haney, Zhong Ma, Alexander L Klibanov, James W Mandell, Kodi S Ravichandran. Nature 2007
573
15

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Mark P Chao, Ash A Alizadeh, Chad Tang, June H Myklebust, Bindu Varghese, Saar Gill, Max Jan, Adriel C Cha, Charles K Chan, Brent T Tan,[...]. Cell 2010
686
15

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Ravindra Majeti, Mark P Chao, Ash A Alizadeh, Wendy W Pang, Siddhartha Jaiswal, Kenneth D Gibbs, Nico van Rooijen, Irving L Weissman. Cell 2009
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.